KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Common Equity: 2015-2025

Historic Common Equity for BeOne Medicines (ONC) over the last 10 years, with Sep 2025 value amounting to $4.1 billion.

  • BeOne Medicines' Common Equity rose 20.18% to $4.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 billion, marking a year-over-year increase of 20.18%. This contributed to the annual value of $3.3 billion for FY2024, which is 5.80% down from last year.
  • BeOne Medicines' Common Equity amounted to $4.1 billion in Q3 2025, which was up 9.52% from $3.8 billion recorded in Q2 2025.
  • In the past 5 years, BeOne Medicines' Common Equity registered a high of $6.1 billion during Q4 2021, and its lowest value of $3.3 billion during Q4 2024.
  • Over the past 3 years, BeOne Medicines' median Common Equity value was $3.5 billion (recorded in 2023), while the average stood at $3.7 billion.
  • Its Common Equity has fluctuated over the past 5 years, first surged by 58.50% in 2021, then dropped by 28.52% in 2022.
  • Over the past 5 years, BeOne Medicines' Common Equity (Quarterly) stood at $6.1 billion in 2021, then decreased by 28.52% to $4.4 billion in 2022, then decreased by 19.30% to $3.5 billion in 2023, then decreased by 5.80% to $3.3 billion in 2024, then grew by 20.18% to $4.1 billion in 2025.
  • Its Common Equity stands at $4.1 billion for Q3 2025, versus $3.8 billion for Q2 2025 and $3.5 billion for Q1 2025.